COMMUNIQUÉS West-GlobeNewswire

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
27/02/2026
• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE [...]
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
27/02/2026
PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“ [...]
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
27/02/2026
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with [...]
MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations
27/02/2026
TOKYO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on the Nasdaq Capital Market: NASDAQ: MRM) announced that the Master [...]
Nkarta to Participate in March Investor Conferences
27/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune [...]
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
27/02/2026
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple [...]
Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale
27/02/2026
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and [...]
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
27/02/2026
MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South [...]
Certara to Participate in Upcoming Investor Conferences
27/02/2026
RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
ADARx Pharmaceuticals Presents Onvuzosiran Data Supporting Potential for Sustained Attack-Free Rates with Reduced Treatment Burden in Patients with HAE
27/02/2026
– Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – – Positive results support ongoing Phase 3 clinical trial – SAN DIEGO, Feb. 27, 2026 ( [...]
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
27/02/2026
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease [...]
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
27/02/2026
Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectively Total Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 [...]
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
27/02/2026
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety [...]
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
27/02/2026
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of [...]
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
27/02/2026
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 study demonstrating [...]
Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium
27/02/2026
Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UC CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. ( [...]
Communiqué de presse: L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil
27/02/2026
L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil La recommandation s’appuie [...]
Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF
27/02/2026
S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec [...]
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
27/02/2026
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 [...]

Pages